mg1113
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 21, 2019 (NCT03855696)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor VIIINHIBITOR
F7 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05493631 | Phase 1 | Aug 24, 2022 | Daegu Catholic University, Green Cross Corporation |
| NCT03855696 | Phase 1 | Jan 21, 2019 | DreamCIS, Green Cross Corporation, Korea University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green Cross Corporation | For profit | 2 | 2 | 1 | 2019 |
| Daegu Catholic University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| DreamCIS | For profit | 1 | 0 | 1 | 2019 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1